Nuvectis Pharma (NVCT) Projected to Release Quarterly Earnings on Tuesday

Key Points

• Nuvectis Pharma is expected to report Q3 2026 results before market open on November 3, with analysts forecasting a loss of $0.22 per share. The company’s conference call is scheduled for November 4 at 9:30 a.m. ET.
• The company reported a Q2 loss of $0.30 per share, missing the consensus estimate of a $0.26 loss. Analysts expect full-year and next-year losses of $1.01 and $1.10 per share, respectively.
• NVCT shares opened at $18.49, compared with a 52-week range of $5.55 to $29.27. Analyst sentiment is Moderate Buy, with an average price target of $36.25, though ratings include one Sell recommendation.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) will likely be issuing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.22) per share for the quarter. Individuals can find conference call details on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:30 AM ET.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04). On average, analysts expect Nuvectis Pharma to post ($1.01) EPS for the current fiscal year and ($1.10) EPS for the next fiscal year.

Nuvectis Pharma Price Performance

Shares of NASDAQ NVCT opened at $18.49 on Tuesday. The business has a fifty day moving average of $21.70 and a two-hundred day moving average of $14.41. Nuvectis Pharma has a 52-week low of $5.55 and a 52-week high of $29.27.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on NVCT shares. Loop Capital set a $40.00 target price on shares of Nuvectis Pharma in a report on Tuesday, September 1st. Roth Capital lifted their price target on shares of Nuvectis Pharma from $20.00 to $33.00 and gave the company a "buy" rating in a report on Monday, July 6th. Lucid Cap Mkts upgraded shares of Nuvectis Pharma to a "strong-buy" rating in a research report on Tuesday, September 1st. UBS Group set a $33.00 price objective on shares of Nuvectis Pharma in a research note on Monday, July 6th. Finally, Cantor Fitzgerald assumed coverage on shares of Nuvectis Pharma in a research note on Monday, August 24th. They set an "overweight" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Nuvectis Pharma currently has an average rating of "Moderate Buy" and an average target price of $36.25.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, with an emphasis on cancers that have limited therapeutic options. The company is headquartered in Fort Lee, New Jersey, and its common stock trades on the Nasdaq Capital Market under the symbol NVCT.

Nuvectis Pharma's lead product candidate is NXP800, an orally administered small-molecule inhibitor of heat shock protein 90 (HSP90). The company is evaluating NXP800 in clinical studies for certain advanced solid tumors, including platinum-resistant ovarian cancer and cholangiocarcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.